Physician profile
Shawna Ann Flanagan
NPI 1699754481
$73,850.95
in general payments reported to CMS, 2019-2025
32 companies · $5,269 in 2025
The $5,269 reported for 2025 was more than what 94% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $260 · 2021: $587 · 2022: $9,427 · 2023: $40K · 2024: $6,206 · 2025: $5,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $4,029 · Travel and Lodging: $960 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,810.28 |
| Food and Beverage | $4,029.39 |
| Travel and Lodging | $959.66 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,542.45 | 2020-2025 | |
| Aclaris Therapeutics, INC. | $10,138.45 | 2019 | |
| Allergan, INC. | $9,228.18 | 2019-2022 | |
| Merz North America, INC. | $1,790.54 | 2019-2024 | Xeomin |
| Revance Therapeutics, INC. | $683.79 | 2024-2025 | Daxi, Daxxify |
| Galderma Laboratories, L.P. | $459.77 | 2019-2025 | Nemluvio, Dysport |
| Sun Pharmaceutical Industries INC. | $352.17 | 2020-2025 | Blu-U, Odomzo |
| Amgen INC. | $266.50 | 2020-2025 | Otezla, Otezla |
| Kerecis Limited | $174.95 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Almirall LLC | $135.38 | 2023-2025 | Klisyri, Seysara |
| Novartis Pharmaceuticals Corporation | $110.47 | 2019-2025 | |
| Organogenesis INC. | $96.87 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.50 | 2020-2024 | Arazlo, Jublia, Cabtreo |
| Dusa Pharmaceuticals, INC. | $72.35 | 2019 | |
| Leo Pharma INC. | $69.29 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $61.05 | 2021-2022 | |
| Incyte Corporation | $61.00 | 2022-2024 | Opzelura |
| Biofrontera INC. | $60.80 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Mimedx Group, INC. | $56.92 | 2024-2025 | |
| Dermavant Sciences, INC. | $52.98 | 2023 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $49.80 | 2021-2022 | |
| Lnhc, INC | $48.77 | 2025 | Zelsuvmi |
| Elekta, INC. | $45.35 | 2023 | Elekta Medical Linear Accelerator |
| Lilly USA, LLC | $42.42 | 2019-2021 | |
| Genzyme Corporation | $39.00 | 2019-2020 | |
| Genentech USA, INC. | $33.83 | 2019 | |
| Vyne Pharmaceuticals INC. | $27.82 | 2021 | |
| Pfizer INC. | $20.54 | 2023 | |
| Celgene Corporation | $19.26 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $17.76 | 2025 | Exparel |
| Pierre Fabre Pharmaceuticals, INC. | $9.31 | 2019 | |
| Prugen, INC. Pharmaceuticals | $8.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawna Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.